OncoZenge AB

8LY

Company Profile

  • Business description

    OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

  • Contact

    Gustavslundsvagen 34
    Bromma167 51
    SWE

    T: +46 8311420

    E: [email protected]

    https://www.oncozenge.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1

Stocks News & Analysis

stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.
stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,997.30168.10-1.83%
CAC 408,216.78135.22-1.62%
DAX 4026,045.37553.27-2.08%
Dow JONES (US)50,666.14942.03-1.83%
FTSE 10010,689.87191.68-1.76%
HKSE23,508.17245.67-1.03%
NASDAQ24,214.78294.97-1.20%
Nikkei 22558,860.43801.59-1.34%
NZX 50 Index14,306.963.190.02%
S&P 5007,316.24100.35-1.35%
S&P/ASX 2008,883.20161.50-1.79%
SSE Composite Index3,584.5817.99-0.50%

Market Movers